Click here for Full Prescribing Information

Indication and Usage

QlosiTM is indicated for the treatment of presbyopia in adults.

 

Important Safety Information

CONTRAINDICATIONS
Hypersensitivity

WARNINGS AND PRECAUTIONS
Advise patients to not drive or operate machinery if vision is not clear (e.g., blurred vision). Exercise caution in night driving and other hazardous occupations in poor illumination.

Rare cases of retinal detachment have been reported with miotics. Examination of the retina is advised in all patients prior to initiation of therapy. Advise patients to seek immediate medical care with sudden onset of flashes of lights, floaters, or vision loss.

QLOSI is not recommended to be used when iritis is present.

QLOSI should not be administered while wearing contact lenses. Remove lenses prior to the installation of QLOSI and wait 10 minutes before reinsertion.

Avoid touching the tip of the vial to the eye or any other surface.

ADVERSE REACTIONS
The most common adverse reactions (5% to 8%) are instillation site pain and headaches.

QLO.00022

© 2024 Orasis Pharmaceuticals Inc. All Rights Reserved.

QLOSI, Orasis Pharmaceuticals, the Orasis Pharmaceuticals logo, and certain other trademarks herein are trademarks of Orasis Pharmaceuticals, Inc.

Privacy Policy | Terms of Service

Indication and Usage
Important Safety Information
Expand

QLOSI™ (pilocarpine hydrochloride ophthalmic solution) 0.4%, for topical ophthalmic use is a cholinergic receptor agonist indicated for the treatment of presbyopia in adults.

CONTRAINDICATIONS
Hypersensitivity

WARNINGS AND PRECAUTIONS
Advise patients to not drive or operate machinery if vision is not clear (e.g., blurred vision). Exercise caution in night driving and other hazardous occupations in poor illumination.

Rare cases of retinal detachment have been reported with miotics. Examination of the retina is advised in all patients prior to initiation of therapy. Advise patients to seek immediate medical care with sudden onset of flashes of lights, floaters, or vision loss.

QLOSI is not recommended to be used when iritis is present.

QLOSI should not be administered while wearing contact lenses. Remove lenses prior to the installation of QLOSI and wait 10 minutes before reinsertion.

Avoid touching the tip of the vial to the eye or any other surface.

ADVERSE REACTIONS
The most common adverse reactions (5% to 8%) are instillation site pain and headaches.